Evidence map›Paper›PMID 32119143›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2020

Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore.

A V Marzano, A Chiricozzi, G Giovanardi, G Argenziano, V Bettoli, L Bianchi, P Dapavo, V Dini, G Fabbrocini, G Micali and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

A V Marzano *UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
A Chiricozzi *Institute of Dermatology, Catholic University - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-6739-0387
G GiovanardiInstitute of Dermatology, Catholic University - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
G ArgenzianoDermatology Unit, University of Campania, Naples, Italy.
V BettoliDermatology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera, University of Ferrara, Ferrara, Italy.ORCID https://orcid.org/0000-0002-2760-4600
L BianchiDepartment of Dermatology, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
P DapavoDermatologia, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
V DiniU.O. Dermatologia, Università di Pisa, Pisa, Italy.
G FabbrociniU.O.C. di Dermatologia, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, Naples, Italy.
G MicaliDermatology Clinic, P.O.G. Rodolico, A.O.U. Policlinico, Vittorio Emanuele, Catania, Italy.
A M OffidaniDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
C PotenzaDermatology Operational Unit "Daniele Innocenzi", Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and medicine, Sapienza University of Rome - Polo Pontino- Latina, Italy.
F PrignanoClinica Dermatologica, ASF Dipartimento di Chirurgia e Medicina Translazionale, Università di Firenze, Ospedale Piero Palagi, Florence, Italy.
G GualbertiAbbVie srl, Rome, Italy.
V SaragagliaAbbVie srl, Rome, Italy.ORCID https://orcid.org/0000-0001-5768-5870
F RongiolettiUnit of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.ORCID https://orcid.org/0000-0002-2227-581X

Funding

AbbVie
6 · The paper itself

Abstract

backgroundHidradenitis suppurativa (HS) is a chronic, debilitating disease with a considerable effect on patient quality of life. Its clinical severity can be measured using different scoring systems; however, few of them include patient-centred parameters.

objectiveTo create a new scoring system for HS that includes a quality-of-life instrument, the HIDRAdisk.

methodsThis post hoc analysis was carried out within the framework of a multicentre, longitudinal, epidemiologic study conducted over 9 months on quality-of-life aspects of HS. The new severity score was created using as reference a question from the Subject Satisfaction Questionnaire (SSQ) concerning the severity of HS as evaluated by the patient. Associated variables were selected using univariable and multivariable logistic regression models. The discriminant capabilities of the final model and of the final score were evaluated by the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test.

resultsThe study population included 308 patients with HS of any severity grade. According to the results of the regression models, the variables associated with the reference SSQ measure were number of inflammatory nodules, abscesses and draining fistulas; the HIDRAdisk score; and the number of subumbilical lesions. The HIDRAscore is obtained by the sum of the scores associated with the number of these parameters. Possible scores range from 0 to 10.

conclusionThe HIDRAscore is a new scoring system for HS severity which, in addition to the clinical evaluation by the physician, includes a validated patient-reported outcome measure, the HIDRAdisk.

Indexed as

Hidradenitis SuppurativaQuality of LifeHumansPatient Reported Outcome MeasuresSeverity of Illness IndexSurveys and Questionnaires

Identifiers

PMID32119143
PMCPMC7607398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.